共 109 条
[1]
Mach F(2020)2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk Eur Heart J. 41 111-188
[2]
Baigent C(2015)Statin-associated muscle symptoms: impact on statin therapy - European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management Eur Heart J. 36 1012-1022
[3]
Catapano AL(2009)Narrative review: statin-related myopathy Ann Intern Med. 150 858-868
[4]
Stroes ES(2010)Statin myopathy: A review of recent progress Curr Opin Rheumatol. 22 644-650
[5]
Thompson PD(2016)Muscle- and skeletal-related side-effects of statins: tip of the iceberg? Eur J Prev Cardiol. 23 88-110
[6]
Corsini A(2010)Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment Drug Saf. 33 171-187
[7]
Joy TR(2013)Intolerance to statins: Mechanisms and management Diabetes Care. 36 S325-S330
[8]
Hegele RA(2019)Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components J Clin Med. 9 22-1849
[9]
Mammen AL(1853)The AKT/mTOR signaling pathway plays a key role in statin-induced myotoxicity Biochim Biophys Acta. 2015 1841-e164
[10]
Amato AA(2007)Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: Results of the POLARIS study Atherosclerosis. 194 e154-1394